Walvax沃森生物

CN
EN

Products List

Walvax has successfully developed 8 licensed vaccines, including recently approved 13-valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13-TT) and Recombinant Human Papillomavirus Bivalent (Types 16,18) Vaccine (HPV-2).

 

Walvax proactively promotes PQ application of its products, and is proceeding with PQ application of multiple products. In 3 to 5 years, Walvax's WHO-PQ will yield fruitful results, which brings its internationalization to a higher level.

Quick Links

Pipeline
13-valent Pneumococcal Polysaccharide Conjugate Vaccine

Prevention of invasive diseases caused by 13 serotypes of Streptococcus pneumoniae for use in infants and children 6 weeks through 5 years of age (below 6 years).

23-valent Pneumococcal Polysaccharide Vaccine

Prevention of invasive diseases caused by 23 serotypes of Streptococcus pneumoniae for use in individuals aged ≥ 2 years who are at increased risk of pneumococcal diseases.